Back to News
Mergers & Acquisitions

Drinks With The Deal: Alec Dawson of Morgan Lewis

|
Published: July 22nd, 2021
M&A lawyer Alec Dawson discusses the opportunities and challenges in the SPAC market and the difficulties of doing deals remotely.

“The SPAC market has almost become a late-stage venture capital market,” R. Alec Dawson said on this week’s Drinks With The Deal podcast. Even a few years ago, said Dawson, an M&A partner at Morgan, Lewis & Bockius LLP in New York, shareholders in the operating companies that combined with special purpose acquisition companies would generally sell a good chunk of their stock in such transactions. Now, those shareholders — whether founders of technology companies or private equity funds — are much more likely to take equity in the entity created by so-called de-SPAC transactions.

Dawson also discussed the challenges the SPAC market faces. SEC pronouncements on the vehicles’ use of warrant accounting and earnings projections “tied up every accounting firm and every big law firm that tried to deal with the problems that raised,” he said, at a time when hundreds of SPACs are seeking merger partners.

Delaware plaintiffs’ lawyers have also focused on perceived problems raised by de-SPAC deals. In response, SPAC boards are starting to get fairness opinions, and their independent directors are retaining separate counsel more frequently. Serial sponsors have started to vary the composition of the boards of their SPACs to make it harder for plaintiffs’ lawyers to challenge director independence, Dawson said.

He predicted that a new set of serial sponsors who come up with different ways to do SPACs may emerge but believes that the structure will persist.

Here’s the podcast:

More podcasts from The Deal are available on iTunesSpotify and on TheDeal.com.

More From Mergers & Acquisitions

Mergers & Acquisitions

Drinks With The Deal: Krishna Veeraraghavan of Paul Weiss

By David Marcus
|
Published: October 14th, 2021
M&A lawyer Krishna Veeraraghavan talked about healthcare dealmaking and the risks of excessive antitrust regulation of combinations between biotech and pharma companies in the Drinks With The Deal podcast.
Mergers & Acquisitions

OpEd: ESG in Due Diligence Is Not Just Another Box to Check

By Deal Contributors
|
Published: October 5th, 2021
With ESG now a day-to-day focus for management and directors across industries, companies would be well-served to undertake a thoughtful assessment of ESG risks when evaluating potential targets in M&A activities.
Activism

CorpGov: Barshay Says Lina Khan Can't Sue Everybody

By Tom Terrarosa
|
Published: October 1st, 2021
The powerhouse corporate attorney handed out some advice to companies, ESG investors and the broader investment community at The Deal's Corporate Governance 2021 conference.